197 related articles for article (PubMed ID: 24444858)
1. Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies.
Yoon W; Alame A; Berri R
Am J Surg; 2014 Mar; 207(3):403-7; discussion 406-7. PubMed ID: 24444858
[TBL] [Abstract][Full Text] [Related]
2. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.
Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spilioitis J; Torres-Melero J; Turaga K; Trout R
Ann Surg Oncol; 2014 Dec; 21(13):4195-201. PubMed ID: 24854493
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination.
Esquivel J; Garcia SS; Hicken W; Seibel J; Shekitka K; Trout R
J Surg Oncol; 2014 Nov; 110(6):656-60. PubMed ID: 24898451
[TBL] [Abstract][Full Text] [Related]
4. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
5. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ
Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923
[TBL] [Abstract][Full Text] [Related]
7. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
[TBL] [Abstract][Full Text] [Related]
8. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Chua TC; Morris DL; Esquivel J
Ann Surg Oncol; 2010 May; 17(5):1330-6. PubMed ID: 20033321
[TBL] [Abstract][Full Text] [Related]
9. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
Omohwo C; Nieroda CA; Studeman KD; Thieme H; Kostuik P; Ross AS; Holter DR; Gushchin V; Merriman B; Sardi A
J Am Coll Surg; 2009 Sep; 209(3):308-12. PubMed ID: 19717034
[TBL] [Abstract][Full Text] [Related]
10. Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC.
Simkens GA; van Oudheusden TR; Nieboer D; Steyerberg EW; Rutten HJ; Luyer MD; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2016 Dec; 23(13):4214-4221. PubMed ID: 27027308
[TBL] [Abstract][Full Text] [Related]
11. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.
Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745
[TBL] [Abstract][Full Text] [Related]
12. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
Wong JF; Tan GH; Wang W; Soo KC; Teo MC
World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
[TBL] [Abstract][Full Text] [Related]
13. Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.
Riss S; Chandrakumaran K; Dayal S; Cecil TD; Mohamed F; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):392-5. PubMed ID: 25238953
[TBL] [Abstract][Full Text] [Related]
14. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: Two pathogenetic types based study.
Yarema R; Fetsych T; Volodko N; Оhorchak M; Petronchak O; Huley R; Mylyan Y; Glehen O
J Surg Oncol; 2018 Jun; 117(8):1806-1812. PubMed ID: 29761503
[TBL] [Abstract][Full Text] [Related]
16. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
Ross A; Sardi A; Nieroda C; Merriman B; Gushchin V
Eur J Surg Oncol; 2010 Aug; 36(8):772-6. PubMed ID: 20561764
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
Teo MC; Tan GH; Tham CK; Lim C; Soo KC
Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Klaver YL; Chua TC; Verwaal VJ; de Hingh IH; Morris DL
J Surg Oncol; 2013 May; 107(6):585-90. PubMed ID: 23280508
[TBL] [Abstract][Full Text] [Related]
20. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
